Atul Ltd posts 92% profit surge, revenue up 25% in Q1FY27
Atul Ltd delivered strong Q1FY27 results with consolidated net profit jumping 92% to ₹253.93 crore and revenue rising 25% to ₹1,847.95 crore. The Performance and Other Chemicals segment drove growth, while standalone profit also more than doubled. The board also appointed Vinayak Deshpande as an independent director.

*this image is generated using AI for illustrative purposes only.
Atul Ltd reported a sharp acceleration in profitability for the first quarter of FY27, with consolidated net profit surging 92% year-on-year to ₹253.93 crore. The chemical manufacturer’s consolidated revenue from operations rose 25% to ₹1,847.95 crore, reflecting robust demand across its key segments. The strong bottom-line growth was underpinned by significant margin expansion and operational efficiency gains during the quarter ended June 30, 2026.
Consolidated Financial Performance
The company’s consolidated earnings before interest, taxes, depreciation, and amortisation (EBITDA) stood at ₹344.74 crore for the quarter, compared to ₹175.16 crore in the same period last year. This represents a substantial improvement in operating leverage. The net profit attributable to owners of the company was ₹245.30 crore, up from ₹127.77 crore in Q1FY26. Basic earnings per share (EPS) more than doubled to ₹83.32 from ₹43.40 in the previous year.
Total comprehensive income for the group reached ₹375.41 crore, driven by both operational profits and other comprehensive income items, including fair value adjustments on equity instruments.
Segment-Wise Highlights
The Performance and Other Chemicals segment continued to be the primary growth engine, contributing ₹1,427.44 crore to segment revenue, a 34% increase from ₹1,066.93 crore in Q1FY26. The segment’s result improved significantly to ₹239.83 crore from ₹100.00 crore year-on-year.
The Life Science Chemicals segment also showed steady growth, with revenue rising to ₹469.23 crore from ₹449.20 crore. Its segment result increased to ₹92.78 crore from ₹68.41 crore in the corresponding period last year.
| Metric | Q1FY27 | Q1FY26 | YoY Change |
|---|---|---|---|
| Consolidated Revenue | ₹1,847.95 cr | ₹1,478.00 cr | +25% |
| Consolidated Net Profit | ₹253.93 cr | ₹132.36 cr | +92% |
| EBITDA | ₹344.74 cr | ₹175.16 cr | +97% |
| EPS (Basic) | ₹83.32 | ₹43.40 | +92% |
Standalone Results
On a standalone basis, Atul Ltd reported a net profit of ₹201.03 crore, up from ₹97.74 crore in Q1FY26. Standalone revenue from operations grew 22% to ₹1,588.60 crore. The company’s total assets under the consolidated structure expanded to ₹8,528.42 crore, indicating continued investment and scale-up in its operations.
Board Appointment
In other developments, the Board of Directors appointed Vinayak Deshpande as an Additional Director and Independent Director, effective August 01, 2026. The appointment is for a period of five consecutive years, subject to shareholder approval. Deshpande brings over four decades of experience in industrial automation and infrastructure projects, having previously served as Managing Director and CEO of Tata Honeywell and Tata Projects.
What the Numbers Show
The disproportionate jump in net profit (92%) compared to revenue growth (25%) highlights significant operating leverage achieved by Atul Ltd in Q1FY27. The EBITDA margin expanded meaningfully, suggesting that the company is benefiting from higher pricing power or optimized input costs. The Performance and Other Chemicals segment’s contribution to profits nearly tripled, indicating this division is currently driving the majority of the group’s value creation.
Historical Stock Returns for Atul
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +4.53% | +4.80% | -1.53% | +9.97% | -4.30% | -30.76% |
Can Atul Ltd sustain the current EBITDA margin expansion in Q2FY27, or was the 92% profit surge driven by one-off favorable input cost dynamics?
How will the appointment of Vinayak Deshpande, with his industrial automation expertise, influence Atul Ltd's capital expenditure strategy and operational efficiency targets for FY28?
Given the disproportionate growth in the Performance and Other Chemicals segment, what specific downstream demand drivers are expected to support its continued dominance over Life Science Chemicals?


































